Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis patients. As seen by two recent large acquisitions for billions of dollars with late-stage myelofibrosis companies, myelofibrosis is a financially lucrative market. This implies that promising results from newly developed medicines might potentially pave the way for licensing prospects as well.
JAKAFI’s dominance in the myelofibrosis treatment
The or...
